知镜 Cognispect · 医学文献与研究工作台

Sodium glucose cotransporter 2 inhibitors may mask malignancy-associated fluorodeoxyglucose uptake in the thyroid on positron emission tomography/computed tomography.

Alanli R, Kucukay MB, Koca AO, Ucmak G, Dogan M.
Revista da Associacao Medica Brasileira (1992) · 2026-11-02 · PMID 42987081

文献摘要

Objective The aim of this study is to assess the effect of sodium glucose cotransporter 2 inhibitors on thyroid fluorodeoxyglucose uptake and maximum standardized uptake values on fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography, and to evaluate potential implications for the interpretation of thyroid incidentalomas. Methods This retrospective study included 262 female breast cancer patients who underwent fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging between July 2020 and July 2025. Patients were stratified into three groups: sodium glucose cotransporter 2 inhibitor users (n=55), diabetic patients using other antidiabetic agents (n=111), and non-diabetic controls (n=96). Thyroid fluorodeoxyglucose uptake was scored present or absent by a single blinded nuclear medicine physician; maximum standardized uptake value was measured only in avid glands (n=106). Results Thyroid fluorodeoxyglucose uptake was less frequent in sodium glucose cotransporter 2 inhibitor users (p Conclusion Sodium glucose cotransporter 2 inhibitor use was independently associated with reduced thyroid fluorodeoxyglucose avidity and lower maximum standardized uptake value, unexplained by glycemic control or concurrent antidiabetic therapy. Clinicians should be aware of this pharmacological masking effect when evaluating thyroid incidentalomas in patients receiving sodium glucose cotransporter 2 inhibitors.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。